Table 3.

Meta-regression analysis for the effect of metformin on SMCC of cardiovascular parameters and NT-ProBNP

	LVMI		LVEF		E/e′ ratio		NT-ProBNP/BNP
	B [95% CI]	p	B [95% CI]	p	B [95% CI]	p	B [95% CI]	p
Intercept only model	− 0.49 [− 0.94; − 0.04]	0.036	0.128 [–0.19; 0.45]	0.45	–0.18 [− 0.387; 0.03]	0.07	− 0.07 [− 0.28; 0.14]	0.44
Metformin dose
1000 mg or less	− 0.287 [–0.7; 0.134]	0.14	–0.23 [− 0.49; 0.03]	0.07	− 0.128 [− 0.59; 0.34]	0.36	NA
> 1000 mg	− 0.7 [− 1.51;0.11]	0.08	0.28 [0.04; 0.52]	0.04	− 0.313 [− 1.2; 0.56]	0.26	− 0.02 [− 0.44; 0.41]	0.92
Duration
6 months or less	− 0.215 [− 0.51; 0.08]	0.12	− 0.02 [− 0.48; 0.43]	0.9	− 0.163 [− 0.5; 0.17]	0.17	− 0.05 [− 0.5; 0.41]	0.79
> 6 months	− 0.4 [− 0.78; − 0.02]	0.04	0.3 [− 0.07; 0.68]	0.09	NA		− 0.07 [− 0.36; 0.21]	0.53
HF
No	− 0.51 [− 1.1; 0.08]	0.09	0.06 [− 0.5; 0.62]	0.81	− 0.19 [− 0.73; 0.36]	0.28	− 0.04 [− 0.26; 0.19]	0.68
Yes	NA		0.23 [0.1; 0.36]	0.004	NA		− 0.08 [− 0.73; 0.56]	0.74
Pooled baseline average (1 unit increase)	0.005 [− 0.02; 0.03]	0.64	− 0.005 [− 0.02; 0.01]	0.34	0.05 [− 0.13; 0.23]	0.35	0.09 ¶ [− 0.05; 0.06]	0.69

Bold values denote statistical significance at the p < 0.05 level

B—regression coefficient (SMCC), CI.L—lower limit for 95% confidence interval, CI.U—upper limit for the 95% confidence interval

HF heart failure

NA: Only one study provided data

^¶Result represents the change in SMCC for each 100-unit increase